Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14421730 | 0.84 | CREBBP (0.36) | CREBBP | |
| SCHEMBL15507913 | 0.78 | CREBBP (0.54) | BRD4CREBBP | |
| SCHEMBL29004246 | 0.78 | CREBBP (0.54) | BRD4CREBBP | |
| SCHEMBL29898373 | 0.78 | CREBBP (0.54) | BRD4CREBBP | |
| SCHEMBL5805634 | 0.78 | CREBBP (0.54) | BRD4CREBBP | |
| SCHEMBL2666096 | 0.70 | CDC7 (0.38) | ADORA3ADORA2AADORA1 | |
| SCHEMBL10081671 | 0.70 | CDC7 (0.38) | — | |
| SCHEMBL5900111 | 0.69 | BRD4 (0.34) | BRD4CREBBP | |
| SCHEMBL24317429 | 0.68 | MTNR1A (0.38) | — | |
| SCHEMBL25059407 | 0.67 | ADORA3 (0.35) | ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576099-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | TRPV1, TRPA1, TRPV2 | BRD4 2304/4885CREBBP 518/4885ADORA3 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.